March 9, 2020 / 12:22 PM / 23 days ago

BRIEF-Vaccinex Announces Expansion of Pepinemab Development Program To Alzheimer's Disease

March 9 (Reuters) - Vaccinex Inc:

* VACCINEX REPORTS FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

* VACCINEX INC - ON-TRACK TO REPORT TOPLINE DATA FROM CLASSICAL-LUNG AND SIGNAL CLINICAL TRIALS THIS YEAR

* VACCINEX INC - ANNOUNCES EXPANSION OF PEPINEMAB DEVELOPMENT PROGRAM INTO ALZHEIMER’S DISEASE

* VACCINEX - CASH AND CASH EQUIVALENTS AND MARKETABLE SECURITIES ON DECEMBER 31, 2019 WERE $2.8 MILLION Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below